Balchem Corporation (NASDAQ:BCPC) Q4 2022 Earnings Call Transcript

And as we look for 2023, we think the range for CapEx will be between 40 million and 50 million depending a little bit on the spend. So that’s kind of where we see the range for CapEx, we still are expanding our capacities surround Vitamin K2 and completing a new facility there, here in 2023, that will drive some incremental expense, but in the range of 40 million to 50 million is where I expect 2023 to come in.

Mitra Ramgopal: Okay, its great. Thanks again for taking the questions.

Operator: There are no further questions at this time. I would now like to turn the call back over to Chief Executive Officer, Ted Harris for closing remarks.

Ted Harris : Great, thanks Darrell. Once again, thank you all very much for joining the call today. We really are pleased with the results for the fourth quarter, particularly given the macroeconomic challenges we’ve been facing. And 2022 was another very strong year for Balchem and one in which we set new records financially, while continuing to make good progress strategically with the company. So, we really appreciate your support through the year as well as your time today. We look forward to reporting out Q1 2023 results in April. Thanks so much for joining. Take care.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.